Vanda Pharmaceuticals (VNDA)
Market Price (3/3/2026): $8.19 | Market Cap: $484.0 MilSector: Health Care | Industry: Biotechnology
Vanda Pharmaceuticals (VNDA)
Market Price (3/3/2026): $8.19Market Cap: $484.0 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -52% | Weak multi-year price returns3Y Excs Rtn is -49% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -151 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -70% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Biotechnology & Genomics, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Show more. | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -4.1% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -51%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -51% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 61% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -50% | ||
| Key risksVNDA key risks include [1] significant financial distress, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -52% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Biotechnology & Genomics, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns3Y Excs Rtn is -49% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -151 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -70% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -4.1% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -51%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -51% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 61% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -50% |
| Key risksVNDA key risks include [1] significant financial distress, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Positive Phase 2 Clinical Trial Results for Tradipitant in GLP-1 Induced Nausea and Vomiting.
Vanda Pharmaceuticals announced positive topline results on November 17, 2025, from its Phase 2 study evaluating tradipitant for the prevention of nausea and vomiting induced by GLP-1 receptor agonist Wegovy. The study met its primary endpoint, demonstrating a 50% relative reduction in vomiting among tradipitant-treated participants compared to placebo. This significant development positions tradipitant as a potential adjunct therapy in the rapidly expanding GLP-1 agonist market and led to an initial 17% rise in Vanda's shares.
2. FDA Approval of NEREUS (Tradipitant) for Motion-Induced Vomiting and Lifting of Clinical Hold.
On December 4, 2025, the FDA lifted a partial clinical hold on Vanda's tradipitant protocol for motion sickness treatment, agreeing that motion sickness is an acute, self-limiting response, which removed the requirement for an additional six-month dog toxicity study. This regulatory development, which allowed for extended clinical studies, was followed by the FDA's approval of NEREUS (tradipitant) for the prevention of vomiting induced by motion by December 30, 2025. This marked the first new oral therapy for motion-induced vomiting prevention in over 40 years and contributed to an 11% rise in VNDA's stock in after-hours trading.
Show more
Stock Movement Drivers
Fundamental Drivers
The 52.4% change in VNDA stock from 11/30/2025 to 3/2/2026 was primarily driven by a 49.6% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3022026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.36 | 8.17 | 52.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 212 | 216 | 1.9% |
| P/S Multiple | 1.5 | 2.2 | 49.6% |
| Shares Outstanding (Mil) | 59 | 59 | 0.0% |
| Cumulative Contribution | 52.4% |
Market Drivers
11/30/2025 to 3/2/2026| Return | Correlation | |
|---|---|---|
| VNDA | 52.4% | |
| Market (SPY) | 0.4% | -8.8% |
| Sector (XLV) | 0.6% | 22.2% |
Fundamental Drivers
The 72.7% change in VNDA stock from 8/31/2025 to 3/2/2026 was primarily driven by a 62.9% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3022026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.73 | 8.17 | 72.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 203 | 216 | 6.2% |
| P/S Multiple | 1.4 | 2.2 | 62.9% |
| Shares Outstanding (Mil) | 59 | 59 | -0.2% |
| Cumulative Contribution | 72.7% |
Market Drivers
8/31/2025 to 3/2/2026| Return | Correlation | |
|---|---|---|
| VNDA | 72.7% | |
| Market (SPY) | 6.7% | 3.3% |
| Sector (XLV) | 15.9% | 21.1% |
Fundamental Drivers
The 71.6% change in VNDA stock from 2/28/2025 to 3/2/2026 was primarily driven by a 60.0% change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 3022026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.76 | 8.17 | 71.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 199 | 216 | 8.7% |
| P/S Multiple | 1.4 | 2.2 | 60.0% |
| Shares Outstanding (Mil) | 58 | 59 | -1.3% |
| Cumulative Contribution | 71.6% |
Market Drivers
2/28/2025 to 3/2/2026| Return | Correlation | |
|---|---|---|
| VNDA | 71.6% | |
| Market (SPY) | 16.5% | 11.8% |
| Sector (XLV) | 7.9% | 26.6% |
Fundamental Drivers
The 26.9% change in VNDA stock from 2/28/2023 to 3/2/2026 was primarily driven by a 55.8% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3022026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.44 | 8.17 | 26.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 254 | 216 | -15.0% |
| P/S Multiple | 1.4 | 2.2 | 55.8% |
| Shares Outstanding (Mil) | 57 | 59 | -4.1% |
| Cumulative Contribution | 26.9% |
Market Drivers
2/28/2023 to 3/2/2026| Return | Correlation | |
|---|---|---|
| VNDA | 26.9% | |
| Market (SPY) | 79.7% | 12.7% |
| Sector (XLV) | 30.5% | 25.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| VNDA Return | 19% | -53% | -43% | 14% | 84% | 1% | -32% |
| Peers Return | -17% | 33% | 10% | -0% | 42% | -8% | 58% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 0% | 83% |
Monthly Win Rates [3] | |||||||
| VNDA Win Rate | 58% | 25% | 42% | 50% | 50% | 33% | |
| Peers Win Rate | 50% | 58% | 53% | 50% | 62% | 13% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| VNDA Max Drawdown | 0% | -56% | -54% | -18% | -18% | -35% | |
| Peers Max Drawdown | -40% | -27% | -30% | -22% | -21% | -15% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: NBIX, ACAD, SUPN, AXSM, HRMY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/2/2026 (YTD)
How Low Can It Go
| Event | VNDA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -84.3% | -25.4% |
| % Gain to Breakeven | 536.4% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -55.3% | -33.9% |
| % Gain to Breakeven | 123.9% | 51.3% |
| Time to Breakeven | 330 days | 148 days |
| 2018 Correction | ||
| % Loss | -61.0% | -19.8% |
| % Gain to Breakeven | 156.5% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -98.4% | -56.8% |
| % Gain to Breakeven | 6234.0% | 131.3% |
| Time to Breakeven | Not Fully Recovered days | 1,480 days |
Compare to NBIX, ACAD, SUPN, AXSM, HRMY
In The Past
Vanda Pharmaceuticals's stock fell -84.3% during the 2022 Inflation Shock from a high on 6/30/2021. A -84.3% loss requires a 536.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Vanda Pharmaceuticals (VNDA)
AI Analysis | Feedback
Here are 1-2 brief analogies for Vanda Pharmaceuticals:
Vanda Pharmaceuticals is like a specialized Biogen, focusing on niche neurological and rare sleep disorders.
Vanda Pharmaceuticals is like a smaller Jazz Pharmaceuticals, specializing in rare sleep and psychiatric disorders.
AI Analysis | Feedback
- Hetlioz (tasimelteon): A medication used to treat Non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis Syndrome.
- Fanapt (iloperidone): An atypical antipsychotic medication prescribed for the treatment of schizophrenia.
AI Analysis | Feedback
Vanda Pharmaceuticals (VNDA) sells primarily to other companies. Its major customers are pharmaceutical wholesale distributors responsible for distributing its products to pharmacies, hospitals, clinics, and other healthcare providers.
- McKesson Corporation (NYSE: MCK)
- Cencora, Inc. (formerly AmerisourceBergen Corporation) (NYSE: COR)
- Cardinal Health, Inc. (NYSE: CAH)
AI Analysis | Feedback
nullAI Analysis | Feedback
Mihael H. Polymeropoulos, MD President, Chief Executive Officer and Chairman of the Board
Dr. Polymeropoulos co-founded Vanda Pharmaceuticals in 2003 in partnership with Care Capital LLC, a biopharmaceuticals-focused investment firm, and Bio*One Capital, an investment arm of the Singapore government. He has served as President, Chief Executive Officer, and Chairman of the Board since 2021, and as President, Chief Executive Officer and Director from 2003 to 2021. Prior to Vanda, he was Vice President and Head of the Pharmacogenetics Department at Novartis AG from 1998 to 2003. He also served as Chief of the Gene Mapping Section at the National Human Genome Research Institute from 1992 to 1998, and co-founded the Integrated Molecular Analysis of Genome Expression (I.M.A.G.E.) Consortium.
Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer
Mr. Moran has served as Senior Vice President, Chief Financial Officer, and Treasurer of Vanda Pharmaceuticals since July 2020. He joined Vanda in September 2010 and held various finance roles, including Vice President, Acting Chief Financial Officer and Treasurer (March 2020 to July 2020) and Vice President and Controller (March 2018 to March 2020). Before joining Vanda, Mr. Moran was a Senior Associate at PricewaterhouseCoopers.
Tim Williams Senior Vice President, General Counsel and Secretary
Mr. Williams has served as Senior Vice President, General Counsel, and Secretary since August 2018. Prior to Vanda, he was Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary at AgNovos Healthcare, a medical device company, from September 2013 to July 2018. From 2009 to 2013, he was Senior Legal Counsel and Assistant Secretary at Stryker Corporation, where he was involved in global M&A, corporate governance, and securities.
Gunther Birznieks Senior Vice President, Business Development
Mr. Birznieks holds the position of Senior Vice President, Business Development at Vanda Pharmaceuticals. A detailed background including founding/managing other companies, selling companies, or patterns of managing private equity-backed companies was not readily available in the search results.
Joakim Wijkstrom Senior Vice President, Chief Marketing Officer
Mr. Wijkstrom has served as Senior Vice President, Chief Marketing Officer since 2019. His prior experience includes serving as Senior Vice President and Chief Marketing Officer at Perry Ellis International, and various leadership roles in advertising agencies.
AI Analysis | Feedback
Vanda Pharmaceuticals (VNDA) faces several key business risks, primarily centered on its financial performance, regulatory challenges, and product-specific competition. First, **profitability and overall financial health** represent a significant risk. The company has demonstrated negative net margins, experienced a 3-year revenue growth decline, and is grappling with ongoing cash burn and quarterly losses. Its Altman Z-Score, which assesses the probability of bankruptcy, has been in the distress zone, indicating potential financial instability within the next two years. Second, **regulatory uncertainty and a history of disputes with the U.S. Food and Drug Administration (FDA)** pose a considerable risk. Vanda has had repeated disagreements with the FDA, which some sources suggest may hinder a constructive working relationship with the agency. While there have been recent positive developments, such as the FDA lifting a partial clinical hold on tradipitant and agreeing to expedited re-reviews for other applications, the outcomes of these regulatory processes for pipeline candidates remain uncertain and critical for future growth. Third, **impending generic competition for key products** threatens Vanda's revenue streams. HETLIOZ, one of Vanda's marketed products, is expected to face generic competition beyond 2026. The loss of exclusivity for this product could lead to a substantial decrease in revenue and a rapid erosion of market share and pricing power, requiring the company to successfully commercialize newer products to offset these losses.AI Analysis | Feedback
The primary clear emerging threat for Vanda Pharmaceuticals is the impending loss of market exclusivity for its flagship product, Hetlioz (tasimelteon). Vanda has settled patent litigation with several generic manufacturers, allowing for the entry of generic tasimelteon products starting in December 2026. As Hetlioz represents the substantial majority of Vanda's current revenue, the introduction of generic competition is expected to significantly erode its market share and revenue. This known and scheduled event constitutes a fundamental threat to the company's financial future as the date of generic entry approaches.
AI Analysis | Feedback
```htmlAddressable Markets for Vanda Pharmaceuticals' Main Products
-
Hetlioz (tasimelteon)
- Non-24-Hour Sleep-Wake Disorder (Non-24): Approximately 70% of totally blind individuals with sleep complaints are not entrained to the 24-hour clock (U.S.).
- Smith-Magenis Syndrome (SMS): No specific market size in patient numbers or dollar value was identified, but it is considered a rare circadian rhythm disorder (U.S.).
-
Fanapt (iloperidone)
- Schizophrenia: The schizophrenia treatment market is described as a lucrative niche (U.S.).
- Bipolar I Disorder: Affects approximately 2.8% of adults in the United States, with total cases of bipolar I disorder depression in the U.S. observed as approximately 935,000 in 2021.
- Vanda projects its psychiatry portfolio, which includes Fanapt, to generate over $750 million annually by 2030.
-
Ponvory (ponesimod)
- Relapsing forms of Multiple Sclerosis (RMS): No specific market size in patient numbers or dollar value was identified (U.S. and Canada).
- Psoriasis (in Phase III development): Over 8 million people are diagnosed with psoriasis (U.S.).
- Ulcerative Colitis (in Phase III development): Estimated prevalence in the U.S. is approximately 2 million individuals.
-
Tradipitant (pipeline product)
- Gastroparesis: An analyst eyed potential peak sales of nearly $900 million if the drug receives FDA approval for this indication.
-
VGT-1849A (pipeline product for polycythemia vera)
- Polycythemia Vera: The market size is expected to reach $2.03 billion by 2032 (global).
AI Analysis | Feedback
Vanda Pharmaceuticals (VNDA) is anticipated to drive future revenue growth over the next two to three years through several key initiatives:
-
Expansion of Fanapt® (iloperidone) Commercialization: The commercial launch of Fanapt® for the acute treatment of bipolar I disorder is a significant driver, with new patient starts showing substantial increases. Vanda is investing in expanding its sales force and marketing efforts for this indication. Additionally, the development of a long-acting injectable (LAI) formulation of Fanapt® is expected to further contribute to the psychiatry portfolio's growth.
-
Launch of Bysanti™ (milsaperidone): Bysanti™, the active metabolite of Fanapt®, is expected to be a major contributor to Vanda's psychiatry franchise. The New Drug Application (NDA) for bipolar I disorder and schizophrenia has been accepted for filing, with a PDUFA target action date of February 21, 2026. This product is seen as having the potential to drive significant future growth.
-
Introduction of Tradipitant for Motion Sickness: Vanda submitted an NDA for tradipitant for motion sickness, which has been accepted for filing with a PDUFA target action date of December 30, 2025. This represents a new product launch that can diversify revenue streams.
-
Commercialization of Imsidolimab for Generalized Pustular Psoriasis: The Biologics License Application (BLA) for imsidolimab in generalized pustular psoriasis is expected to be submitted in 2025, with potential market entry in the coming years. This will strengthen Vanda's anti-inflammatory portfolio.
-
Indication Expansion for PONVORY®: Vanda is exploring additional indications for its multiple sclerosis drug, PONVORY®. Investigational New Drug (IND) applications for PONVORY® in the treatment of psoriasis and ulcerative colitis were accepted in the fourth quarter of 2024, indicating potential for revenue growth through market expansion for an existing product.
AI Analysis | Feedback
Outbound Investments
- Vanda Pharmaceuticals completed the acquisition of the U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals Ltd. (Janssen) for $100.0 million in December 2023.
Capital Expenditures
- Vanda Pharmaceuticals reported capital expenditures of $2 million in 2020, $1 million in 2021, $1 million in 2022, $0 million in 2023, and $0 million in 2024.
- Projected capital expenditures are $1 million for 2025, $1 million for 2026, and $1 million for 2027.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Vanda Pharmaceuticals Earnings Notes | 12/16/2025 | |
| Would You Still Hold Vanda Pharmaceuticals Stock If It Fell 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to VNDA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 42.00 |
| Mkt Cap | 3.5 |
| Rev LTM | 754 |
| Op Inc LTM | 33 |
| FCF LTM | 85 |
| FCF 3Y Avg | 91 |
| CFO LTM | 135 |
| CFO 3Y Avg | 108 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 16.9% |
| Rev Chg 3Y Avg | 25.9% |
| Rev Chg Q | 19.8% |
| QoQ Delta Rev Chg LTM | 4.7% |
| Op Mgn LTM | 2.4% |
| Op Mgn 3Y Avg | 1.3% |
| QoQ Delta Op Mgn LTM | -0.6% |
| CFO/Rev LTM | 14.8% |
| CFO/Rev 3Y Avg | 13.1% |
| FCF/Rev LTM | 9.9% |
| FCF/Rev 3Y Avg | 11.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.5 |
| P/S | 4.1 |
| P/EBIT | 1.8 |
| P/E | 3.4 |
| P/CFO | 11.3 |
| Total Yield | 1.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.2% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -6.0% |
| 3M Rtn | 1.7% |
| 6M Rtn | 8.5% |
| 12M Rtn | 23.4% |
| 3Y Rtn | 29.5% |
| 1M Excs Rtn | -5.9% |
| 3M Excs Rtn | 0.1% |
| 6M Excs Rtn | 2.5% |
| 12M Excs Rtn | 7.4% |
| 3Y Excs Rtn | -45.4% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA220358 | BYSANTI | milsaperidone | tablet | 2202026 | 41.8% | 41.8% | 41.8% | 41.8% | 41.8% |
| NDA220152 | NEREUS | tradipitant | capsule | 12302025 | 16.2% | 16.2% | 16.2% | 16.2% | 16.2% |
| NDA213498 | PONVORY | ponesimod | tablet | 3182021 | 14.7% | -4.6% | -29.4% | -61.7% | -52.1% |
| NDA214517 | HETLIOZ LQ | tasimelteon | suspension | 12012020 | 45.5% | 44.3% | 29.3% | -11.2% | -33.8% |
| NDA205677 | HETLIOZ | tasimelteon | capsule | 1312014 | 9.7% | 6.3% | -15.9% | -35.5% | -38.2% |
| NDA022192 | FANAPT | iloperidone | tablet | 5062009 | 1,386.1% | 814.8% | 650.9% | 616.7% | 656.5% |
Price Behavior
| Market Price | $8.17 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 04/12/2006 | |
| Distance from 52W High | -8.3% | |
| 50 Days | 200 Days | |
| DMA Price | $7.47 | $5.46 |
| DMA Trend | up | up |
| Distance from DMA | 9.3% | 49.6% |
| 3M | 1YR | |
| Volatility | 125.8% | 77.3% |
| Downside Capture | -318.15 | 43.08 |
| Upside Capture | 16.13 | 91.56 |
| Correlation (SPY) | -7.5% | 12.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.41 | -1.58 | -0.90 | 0.31 | 0.47 | 0.55 |
| Up Beta | 2.32 | 2.84 | 2.66 | 1.60 | 0.21 | 0.30 |
| Down Beta | 0.41 | -3.37 | -1.92 | 0.65 | 0.67 | 0.70 |
| Up Capture | 13% | -48% | 71% | 104% | 99% | 37% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 12 | 23 | 35 | 66 | 121 | 343 |
| Down Capture | -214% | -291% | -346% | -106% | 53% | 89% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 9 | 18 | 26 | 56 | 123 | 380 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VNDA | |
|---|---|---|---|---|
| VNDA | 74.2% | 77.1% | 1.03 | - |
| Sector ETF (XLV) | 9.1% | 17.4% | 0.35 | 26.6% |
| Equity (SPY) | 18.4% | 19.3% | 0.75 | 11.8% |
| Gold (GLD) | 86.5% | 25.7% | 2.41 | 7.8% |
| Commodities (DBC) | 16.5% | 17.1% | 0.73 | 4.2% |
| Real Estate (VNQ) | 7.1% | 16.6% | 0.24 | 11.5% |
| Bitcoin (BTCUSD) | -22.3% | 45.0% | -0.43 | 6.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VNDA | |
|---|---|---|---|---|
| VNDA | -15.3% | 59.1% | -0.05 | - |
| Sector ETF (XLV) | 8.5% | 14.5% | 0.40 | 26.5% |
| Equity (SPY) | 13.6% | 17.0% | 0.63 | 19.8% |
| Gold (GLD) | 23.9% | 17.2% | 1.14 | 5.9% |
| Commodities (DBC) | 11.1% | 19.0% | 0.47 | 2.0% |
| Real Estate (VNQ) | 5.1% | 18.8% | 0.17 | 21.2% |
| Bitcoin (BTCUSD) | 6.2% | 56.8% | 0.33 | 9.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VNDA | |
|---|---|---|---|---|
| VNDA | 0.2% | 55.2% | 0.22 | - |
| Sector ETF (XLV) | 10.8% | 16.5% | 0.54 | 31.6% |
| Equity (SPY) | 15.3% | 17.9% | 0.73 | 27.1% |
| Gold (GLD) | 15.6% | 15.6% | 0.84 | 3.5% |
| Commodities (DBC) | 8.9% | 17.6% | 0.42 | 8.4% |
| Real Estate (VNQ) | 6.5% | 20.7% | 0.28 | 23.3% |
| Bitcoin (BTCUSD) | 65.1% | 66.8% | 1.05 | 7.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/11/2026 | -17.6% | -17.9% | |
| 10/29/2025 | -20.1% | -17.9% | -7.2% |
| 7/31/2025 | -8.8% | -9.6% | 0.6% |
| 5/7/2025 | -3.7% | -10.5% | 5.3% |
| 2/13/2025 | -6.0% | -5.7% | 8.1% |
| 11/6/2024 | 2.7% | 11.7% | -1.0% |
| 7/31/2024 | -3.4% | -11.0% | -10.6% |
| 5/8/2024 | -6.5% | 0.0% | 14.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 9 | 11 |
| # Negative | 17 | 16 | 13 |
| Median Positive | 6.6% | 7.9% | 6.3% |
| Median Negative | -6.0% | -10.7% | -11.0% |
| Max Positive | 21.2% | 20.0% | 23.1% |
| Max Negative | -21.9% | -18.4% | -23.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/12/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/14/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/08/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/09/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Polymeropoulos, Mihael Hristos | President and CEO | Direct | Buy | 8082025 | 4.15 | 10,000 | 41,500 | 9,693,284 | Form |
| 2 | Mitchell, Stephen Ray | Direct | Sell | 6162025 | 4.59 | 7,000 | 32,130 | 445,606 | Form | |
| 3 | Polymeropoulos, Mihael Hristos | President and CEO | Direct | Buy | 5212025 | 4.40 | 10,000 | 43,995 | 10,232,098 | Form |
| 4 | Polymeropoulos, Mihael Hristos | President and CEO | Direct | Buy | 5192025 | 4.22 | 20,000 | 84,472 | 9,780,721 | Form |
| 5 | Polymeropoulos, Mihael Hristos | President and CEO | Direct | Buy | 3062025 | 5.01 | 10,000 | 50,150 | 11,513,091 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.